Janssen Pharmaceuticals has agreed to pay the state of Montana $5.9 million in a Risperdal settlement. The state’s attorney general Tim Fox brought the Risperdal lawsuits against the Johnson & Johnson subsidiary, alleging that the company promoted the antipsychotic medication for unapproved and off-label uses. The funds will be divided among hospitals, courts and Risperdal awareness groups.
Risperdal has only been approved to treat schizophrenia, though the company allegedly promoted it for several other uses, including unapproved use in children. Risperdal side effects, such as gynocomastia in children and adolescents, have become a great concern for doctors and patients.
Gynocomastia is a condition in which males development extra breast tissue due to an increase in the hormone prolactin. The condition can also lead to lactation in males. As many as 25% of gynocomastia cases are linked to medications, including Risperdal.